Alnylam Pharmaceuticals

One-line summary: RNAi/TTR-silencer leader (ticker ALNY); tracked as the perceived winner of the ATTR-CM silencer market after eplontersen's failure.

What it is

RNA-interference biotech; TTR silencer franchise (vutrisiran/Amvuttra) plus next-gen nucresiran; leader in transthyretin amyloidosis silencing.

Why it matters to stock-market

Central tradeable in eplontersen-failure-to-alnylam-silencer-consolidation — AstraZeneca/Ionis' eplontersen null on background tafamidis removed a competitor and the market read ALNY as owning the silencer market (+17%). Load-bearing risk: the same null could threaten ALNY's own adjunctive nucresiran outcomes trial.

Key facts

• Ticker: ALNY (NASDAQ)
• vutrisiran carries a ~20–30% royalty to Sanofi; nucresiran is the royalty-free next-gen bet.
• Also a tau player + orphan-launch exemplar. john-maraganore in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 notes Alnylam "has a program targeting Tau which is intrathecal" (vs Arrowhead's trans-BBB IV shuttle) — so ALNY carries CNS/Alzheimer's optionality alongside the TTR franchise. Separately, matt-gline cited Alnylam as a model for successful orphan-drug launches: "watching a number of other companies, including Alnylam, launch drugs extremely successfully, especially in this kind of orphan zone."

Sources

• 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026
• 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026

Related

• eplontersen-failure-to-alnylam-silencer-consolidation
• bridgebio
• biogen-tau-failure-to-brain-shuttle-rerate — the tau modality question Alnylam's intrathecal program feeds into